Hansoh Pharmaceutical Group Co Ltd (3692) fair value: what the stock is really worth
We calculate from audited financials what Hansoh Pharmaceutical Group Co Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Hansoh Pharmaceutical Group Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.
How to read this chart
60‑month range HK$9.09 – HK$43.08 · fair‑value band HK$25.01 – HK$49.09 · the HK$35.56 price screens below the HK$37.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 18, 2026.
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China.
Show more
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.
Stock analysis
Hansoh Pharmaceutical Group Co Ltd (3692) currently trades at HK$35.56, while our model-based Fair Value estimate is HK$37.77, implying the stock looks roughly 5.9% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$19.78 per share, and 0 of the 26 models we run sit above the HK$35.56 price.
Bear case: the Asset-Based group reads lowest at HK$3.91, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: HK$25.01 (bear) to HK$49.09 (bull), the price of HK$35.56 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Hansoh Pharmaceutical Group Co Ltd reported revenue of 15.0B CNY in FY2025 versus 9.9B CNY in FY2021, a compound +10.9%/yr. Reported net income was 5.6B CNY in FY2025, compounding +19.6%/yr from FY2021.
Key figures
Market cap HK$213B (≈ $27.1B) · P/E ratio 30.7 · P/S ratio 11.3 · EPS (TTM) HK$0.5300 · Dividend yield 1.1% · Net margin 37.0% · Return on equity 17.4% · Return on assets (EBIT) 11.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 20% below its 52-week high and 36% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 6%, 3692 screens cheaper than that median.
Fair Value models
Bear HK$25.01Fair Value HK$37.77Bull HK$49.09
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.1031 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+22.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+18.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.6%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.16% vs 14%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 36%
2025 sits 71% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.1%
Yearly sales growth analysts expect, extended to five years.
Compare Hansoh Pharmaceutical Group Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside−55% · Below median
Profitability
Return on equity (TTM)17% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)37% · Top 25%
Operating margin (TTM)30% · Top 25%
Growth and dividend
Revenue growth32% · Top 25%
Dividend yield (TTM)1.1% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hansoh Pharmaceutical Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/3692
Frequently asked questions
Is Hansoh Pharmaceutical Group Co Ltd (3692) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of HK$37.77 versus a price of HK$35.56, about +6% upside (fairly valued).
What is the fair value of 3692?
Our model-based fair value for Hansoh Pharmaceutical Group Co Ltd is HK$37.77 (as of Sep 18, 2026), built from audited fundamentals. The current price: HK$35.56.
What is the quality score of 3692?
Hansoh Pharmaceutical Group Co Ltd has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hansoh Pharmaceutical Group Co Ltd (3692)?
Our model-based price target is the fair value of HK$37.77 (as of Sep 18, 2026) from 26 valuation models. Cautious scenario HK$25.01, optimistic scenario HK$49.09. It is a calculation from audited fundamentals, not an analyst target.
What is the Hansoh Pharmaceutical Group Co Ltd stock forecast for 2026?
Our models put fair value at HK$37.77, about +6% upside versus a price of HK$35.56 (fairly valued). Cautious scenario HK$25.01, optimistic scenario HK$49.09. The calculation is refreshed regularly with new filings.
What is the revenue of Hansoh Pharmaceutical Group Co Ltd (3692)?
Hansoh Pharmaceutical Group Co Ltd reported trailing-twelve-month revenue of about HK$15.0B (latest available figure, as of Sep 18, 2026).
Does Hansoh Pharmaceutical Group Co Ltd pay a dividend?
Hansoh Pharmaceutical Group Co Ltd currently shows a dividend yield of about 1.09% relative to its recent price (as of Sep 18, 2026).
What growth is priced into Hansoh Pharmaceutical Group Co Ltd (3692)?
For today's price to be fair in a discounted-cash-flow model, Hansoh Pharmaceutical Group Co Ltd would have to grow free cash flow by +12.5 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.6 % per year. As of Sep 18, 2026.
What discount rate (WACC) does the fair value of 3692 use?
Our models discount Hansoh Pharmaceutical Group Co Ltd at 8.6 %: a base by market capitalisation (large), damped by beta 0.52, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hansoh Pharmaceutical Group Co Ltd that is +12.5 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Hansoh Pharmaceutical Group Co Ltd (3692) delivered so far?
Over the past 5 years revenue at Hansoh Pharmaceutical Group Co Ltd grew +11.6 % a year. The price currently implies +12.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hansoh Pharmaceutical Group Co Ltd (3692) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Hansoh Pharmaceutical Group Co Ltd (+12.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hansoh Pharmaceutical Group Co Ltd (3692)?
The free-cash-flow yield on the price is 3.05 %: that much free cash flow Hansoh Pharmaceutical Group Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hansoh Pharmaceutical Group Co Ltd (3692)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hansoh Pharmaceutical Group Co Ltd it is HK$37.77 per share (as of Sep 18, 2026), against a price of HK$35.56. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Hansoh Pharmaceutical Group Co Ltd stock overvalued or undervalued in 2026?
As of Sep 18, 2026, 3692 trades below its calculated fair value: price HK$35.56, fair value HK$37.77, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3692?
No. The price is what the market pays today (HK$35.56); the fair value is what the company's own numbers justify (HK$37.77). For Hansoh Pharmaceutical Group Co Ltd the two are HK$2.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hansoh Pharmaceutical Group Co Ltd worth?
The market values Hansoh Pharmaceutical Group Co Ltd at about HK$213B (market capitalisation, as of Sep 18, 2026). Per share that is HK$35.56; our models calculate a fair value of HK$37.77 per share.
What do the bullish and bearish scenarios say about 3692?
Our models span a range for Hansoh Pharmaceutical Group Co Ltd: cautious scenario HK$25.01, base HK$37.77, optimistic HK$49.09 per share (as of Sep 18, 2026, price HK$35.56). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 3692?
Hansoh Pharmaceutical Group Co Ltd trades at a price-to-earnings ratio of 30.7 (as of Sep 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$37.77 is built from several models across several years. Other multiples: P/B 5.6, P/S 13.2, EV/EBITDA 34.0.
How solid is the balance sheet of Hansoh Pharmaceutical Group Co Ltd (3692)?
Balance-sheet figures for Hansoh Pharmaceutical Group Co Ltd (as of Sep 18, 2026): return on equity 17.4%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 3692 from its 52-week high?
Hansoh Pharmaceutical Group Co Ltd trades at HK$35.56, about 20% below its 52-week high of HK$44.22 and 36% above the low of HK$26.11 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of HK$37.77 is for.
Which stocks are comparable to Hansoh Pharmaceutical Group Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hansoh Pharmaceutical Group Co Ltd stock attractive at the current price?
The data as of Sep 18, 2026: price HK$35.56, calculated fair value HK$37.77 (+6%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3692 calculated?
We run Hansoh Pharmaceutical Group Co Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$37.77, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Hansoh Pharmaceutical Group Co Ltd currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hansoh Pharmaceutical Group Co Ltd (3692)?
The closing price on Sep 21, 2026 was HK$35.56. Our model-based fair value is HK$37.77, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hansoh Pharmaceutical Group Co Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$25.01 to HK$49.09) leaves room in how you read the outcome.
Key figures of Hansoh Pharmaceutical Group Co Ltd
How large is the market capitalisation of Hansoh Pharmaceutical Group Co Ltd (3692)?
The market capitalisation of Hansoh Pharmaceutical Group Co Ltd is HK$213B (≈ $27.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hansoh Pharmaceutical Group Co Ltd (3692)?
The price-to-sales ratio of Hansoh Pharmaceutical Group Co Ltd is 11.3 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hansoh Pharmaceutical Group Co Ltd (3692)?
Earnings per share at Hansoh Pharmaceutical Group Co Ltd are HK$0.5300 (price ÷ EPS = P/E 30.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hansoh Pharmaceutical Group Co Ltd (3692)?
The dividend yield of Hansoh Pharmaceutical Group Co Ltd is 1.1% (payout 73.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hansoh Pharmaceutical Group Co Ltd (3692)?
The net margin of Hansoh Pharmaceutical Group Co Ltd is 37.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hansoh Pharmaceutical Group Co Ltd (3692)?
The return on equity (ROE) of Hansoh Pharmaceutical Group Co Ltd is 17.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hansoh Pharmaceutical Group Co Ltd (3692)?
On an EBIT basis the return on assets of Hansoh Pharmaceutical Group Co Ltd is 11.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hansoh Pharmaceutical Group Co Ltd (3692)?
The operating margin of Hansoh Pharmaceutical Group Co Ltd is 29.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hansoh Pharmaceutical Group Co Ltd (3692)?
Revenue at Hansoh Pharmaceutical Group Co Ltd is growing +32.0% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hansoh Pharmaceutical Group Co Ltd (3692)?
Earnings per share at Hansoh Pharmaceutical Group Co Ltd are growing +45.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Hansoh Pharmaceutical Group Co Ltd (3692) hold?
Hansoh Pharmaceutical Group Co Ltd holds more cash than debt, HK$3.3B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Hansoh Pharmaceutical Group Co Ltd in the live analysis
One click puts Hansoh Pharmaceutical Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 18, 2026